title: VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
abstract: We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen.
authors.affiliation: Vanderbilt University Medical Center, 685 PRB, 2220 Pierce Avenue, Nashville, TN 37232, United States. d.carbone@vanderbilt.edu
authors.forename: David P
authors.initials: DP
authors.lastname: Carbone
authors.forename: J Stuart
authors.initials: JS
authors.lastname: Salmon
authors.forename: Dean
authors.initials: D
authors.lastname: Billheimer
authors.forename: Heidi
authors.initials: H
authors.lastname: Chen
authors.forename: Alan
authors.initials: A
authors.lastname: Sandler
authors.forename: Heinrich
authors.initials: H
authors.lastname: Roder
authors.forename: Joanna
authors.initials: J
authors.lastname: Roder
authors.forename: Maxim
authors.initials: M
authors.lastname: Tsypin
authors.forename: Roy S
authors.initials: RS
authors.lastname: Herbst
authors.forename: Anne S
authors.initials: AS
authors.lastname: Tsao
authors.forename: Hai T
authors.initials: HT
authors.lastname: Tran
authors.forename: Thao P
authors.initials: TP
authors.lastname: Dang
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D018450:Disease Progression; D018572:Disease-Free Survival; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D057285:Precision Medicine; D011237:Predictive Value of Tests; D020543:Proteome / Q000145:classification / Q000378:metabolism; D011799:Quinazolines / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D020543:Proteome; D011799:Quinazolines; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride